Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- CV Therapeutics, Inc. Q3 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Your first question is from the line of Jim Birchenough. Jim Birchenough – Barclays Capital Hi, guys, congratulations on the label expansion. Louis Lange Thank you. Jim Birchenough – Barclays Capital So, just a few questions. Number one, just wondering how you're...
- Earnings calls 2008-11-19
Additional Resources
- Heart failure patients respond well to beta-blocker drugs.
- M2 PRESSWIRE-13 July 2004-YALE UNIVERSITY: Heart failure patients respond well to beta-blocker drugsC1994-2004 M2 COMMUNICATIONS LTD RDATE:07122004 New Haven, Conn. -- Heart failure patients who undergo beta-blocker therapy tolerated the treatment well and had less heart failure deterioration than placebo drugs,...
- Research articles 2004-07-13
- US DEPT OF HHS: NHLBI-VA study finds no heart fa failure survival increase with Beta-Blocker.
- M2 PRESSWIRE-11 November 1999-US DEPT OF HHS: NHLBI-VA study finds no heart failure survival increase with Beta-Blocker C1994-99 M2 COMMUNICATIONS LTD RDATE:101199 ATLANTA -- A study sponsored by the National Heart, Lung, and Blood Institute NHLBI and the Department of Veterans...
- Research articles 1999-11-11
- Doctors say heart patients denied life-saving drug.
- Jun 23, 2003 (The Mercury - ABIX via COMTEX) Heart specialists have indicated that Australian patients are being denied drug treatments which can significantly prolong life. A meeting of the European Society of Cardiology heard that survival rates increase by 20 if heart failure...
- Research articles 2003-06-24
- Case Study: Multislice CT With Speed4D Technology - Diagnosis of a Coronary Anomaly
- A 64-year-old male patient is suffering from atypical angina. In cardiac catheter it was impossible to demonstrate the course of the circumflex coronary artery. Coronary CT angiography was performed to answer this question. Coronary CT angiography with 16-slice CT is a standard application with pre defined and standardized protocols. Preparation...
- Case studies 2003-01-01
- Alcon Receives Positive Opinion for DuoTrav™ Eye Drops Solution from CHMP
- FORT WORTH, Texas -- Alcon, Inc. (NYSE:ACL) announced that the Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion on the initial marketing authorization for DuoTravTM solution (travoprost 0.004%/timolol 0.5%). One daily drop of DuoTravTM eye drops solution lowers intraocular pressure IOP in two distinct ways...
- Research articles 2006-02-24
- Sepracor Awarded Patent For S-Metoprolol, Its Ninth U.S. Patent For An Improved Form Of An Fda-Approved Drug
- MARLBOROUGH, Mass.--BUSINESS WIRE-- Feb. 1, 1995 -- Sepracor Inc., (NASDAQ: SEPR), today announced that it has been granted its ninth U.S. patent for an improved form of an FDA-approved drug. The patent, No. 5,362,757, covers the composition of matter and method of use of S-metoprolol, the single-isomer version of...
- Research articles 1995-02-01
- Beta-Blocker Use in Aberdeen, S.D., Area Exceeds State Average.
- By Scott Waltman, American News, Aberdeen, S.D. Knight Ridder/Tribune Business News By Scott Waltman, American News, Aberdeen, S.D. Knight Ridder/Tribune Business News
- Research articles 2002-10-15
- Northwest Briefs.(Business)
- Akorn, CIBA Vision sign pact BUFFALO GROVE - Akorn Inc. of Buffalo Grove said Friday it entered a marketing services contract with CIBA Vision Corp. for net U.S. sales of the ophthalmic beta-blocker Ocupress. The drug is used to lower intraocular pressure caused by...
- Research articles 2000-01-08
- Ciba-Geigy's U.S. generics arm goes head to head with ICI's Tenormin. (Geneva Pharmaceuticals receives approval to market atenolol, generic version of Imperial Chemical Industries PLC's antihypertensive drug Tenormin)(News) (Brief Article)
- Ciba-Geigy's Basel generics firm, Geneva Pharmaceuticals (Broomfield, CO), has received Food & Drug Administration Washington approval to make and sell atenolol, its generic version of ICI's antihypertensive drug Tenormin, in the U.S. ICI's U.S. patent covering treatment of angina with Tenormin expired last week. ...
- Research articles 1991-10-02
- ICI hypertension patent invalid, rules U.S. court. (Imperial Chemical Industries)
- ICI hypertension patent invalid, rules U.S. court A U.S. federal district court has ruled invalid ICI's patent covering the use of the beta-blocker atenolol--marketed as Tenormin-- to treat hypertension, an application that accounts for 85% of sales. If upheld, the decision will allow competing generic products...
- Research articles 1991-11-20
- North Korea shooter fails drugs test at Olympics
- BEIJING, AFP — North Korea's Kim Jong-Su, who won silver and bronze medals in the Olympics shooting, has failed a doping test, International Olympic Committee IOC spokeswoman Giselle Davies announced on Friday. Kim, who won a silver medal in the men's 50m pistol and bronze in the 10m pistol,...
- Research articles 2008-08-14
- Forest Laboratories: Finding Ways to Bring Drugs to Market — Fast
- Pfizer may be big, but Forest Laboratories is nimble. The smaller company competes by ushering drugs through FDA red tape in record time. Giant: Pfizer Shadow Success: Forest Laboratories, Inc. Pfizer market cap: $96.56 billion;...
- Articles 2009-06-10
- Is America's health system getting better?
- QUALITY OF CARE The quality of care and service from accredited managed care plans has improved substantially over the last three years, girding to the National Committee for Quality Assurance. For example, just 62.5 percent of patients who survived a heart attack in 1996 later received a beta blocker prescription....
- Research articles 2002-11-08
- Big picture in mind, NCQA gives plans a break.(National Committee for Quality Assurance' Health Plan Employer Data and Information Set)
- Oct 1996 revisions to the National Committee for Quality Assurance' Health Plan Employer Data and Information Set are designed to remove some of the many small obstacles to the accurate evaluation of health maintenance organizations. HMOs had been penalized when patients delay in starting beta-blocker drug treatment or when seniors...
- Research articles 1996-11-18
- New & approved: Coreg biotronik home monitoring system
- Coreg (carvedilol, GlaxoSmithKline) The first [beta]-blocker to be approved for the treatment of severe congestive heart failure and the first shown to reduce morbidity and mortality in this population. Approved for mild to moderate CHF in 1997. * Recommended dosage: Initial dose is 3.125 mg twice a...
- Research articles 2001-12-15
- Flat-Lining Quality And The Implications For Health Reform
- As Congress prepares for an historic floor debate over health care reform, those of us who have worked in the trenches to measure and improve the quality of care are watching with a mix of anticipation and concern. Reform has the potential to significantly improve the transparency and, ultimately, the...
- News items 2009-10-22
- Mozilla blocks Microsoft's sneaky Firefox plug-in
- Computerworld - Mozilla late Friday blocked the Microsoft-made software that had put Firefox users at risk from attack. The two-part Microsoft component -- an add-on dubbed ".NET Framework Assistant" and a plug-in named "Windows Presentation Foundation" -- have been blocked by Mozilla as a precautionary measure, said Mike Shaver, the...
- News items 2009-10-18
- << Previous
- page 1 of 1
- Next >>
